Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Drug Therapy × NET × 1 year × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 80 Thoracic 73 Breast 33 Gynecologic 21 Head & Neck 19 Genitourinary 12 Other solid neoplasm 9 Other hematologic neoplasm 9 Lymphoid 9 Sarcoma 7 CNS 7 Tumor-Agnostic 6 Dermatologic 3 Endocrine 2 Plasma cell 1 Other 1 NET 1

Conditions

Neuroendocrine Tumors 1 Carcinoma, Neuroendocrine 1

Interventions

lutetium Lu 177 dotatate 24 Magnetic Resonance Spectroscopy 14 Everolimus 11 Specimen Handling 9 pembrolizumab 7 Nivolumab 7 cabozantinib 5 Capecitabine 5 177Lu-octreotide, DOTA(0)-Tyr(3)- 5 surufatinib 4 gallium Ga 68 dotatate 4 amino-acid, glucose, and electrolyte solution 4 Octreotide 4 Ipilimumab 4 Injections 4 Fluorodeoxyglucose F18 4 X-Rays 3 Temozolomide 3 Cyclophosphamide 3 Carboplatin 3 tislelizumab 2 pasireotide 2 olaparib 2 lenvatinib 2 lanreotide 2 fludarabine phosphate 2 fludarabine 2 copper dotatate CU-64 2 atezolizumab 2 Surveys and Questionnaires 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04464122 2025-04-03

REBORN

University of Roma La Sapienza

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡